You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury
SBC: PROTHERA BIOLOGICS, INC. Topic: 105Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Renal Therapeutic Angiogenesis Using the Novel Biologic ELP-VEGF
SBC: LEFLORE TECHNOLOGIES LLC Topic: 400Abstract.Chronic kidney disease (CKD) is a progressive disorder affecting almost 14% of the general population, and this disease has shown a relentless growth over the past 2 decades. Patients with CKD have higher rates of hospitalization, greater mortality, shorter life expectancy, and their healthcare costs are up to 5 times more expensive than non-CKD patients. Thus, treatments to slow, halt, o ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)
SBC: BIOSTRATAGIES LC Topic: 105PROJECT SUMMARY In this Direct-to-Phase II SBIR, BioStrategies LC proposes to advance the development of a novel AAV- based gene therapy for mucopolysaccharidosis type IIIA (MPS IIIA, also known as Sanfilippo A syndrome). In contrast to other gene therapies in development for MPS IIIA, BioStrategies’ approach is designed to achieve a systemic therapeutic effect, including delivery of a functiona ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A proprietary digital platform for precision patient identification and enrollment of clinical trials for rare kidney diseases
SBC: Nephropathology Associates, PLC Topic: 400Project Summary The goal of this Direct to Phase II program is to develop and test the efficacy of a Precision Medicine Clinical Trials Enrollment Platform for kidney diseases. Approximately half of randomized controlled trials do not meet their recruiting target. Enrolling trials targeting rare kidney diseases is particularly challenging with many conditions subject to stratification and sub-typi ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Advanced Development of Gemini-DHAP
SBC: SFC FLUIDICS, INC. Topic: 200Advanced Development of GeminiTM-DHAP Project Summary:The Specific Aim of this Direct to Phase II project is to develop a discrete, low-profile, dual hormone artificial pancreas device, the GeminiTM-DHAP, using SFC Fluidics' enabling microfluidic technologies to deliver both insulin and glucagon as recommended by a dual-hormone algorithm in response to continuous glucose monitor readings. The Gemi ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Previvors Recharge: A Resilience Program for Cancer Previvors
SBC: Pro-Change Behavior Systems, Inc. Topic: 102It is estimated that approximately 5-10% of all diagnosed cancers are caused by Hereditary Cancer Syndromes (HCS) that are associated with germline mutations (inherited genetic mutations passed directly from a parent to a child that create a genetic predisposition to certain types of cancer). Recent epidemiologic models indicate that 1 in 279 people may be carriers of one of the most common HCS, a ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
100 Additional fresh samples for verification of assay to replace the original proposed banked samples that cannot be used due to repeated exposure to freezing and thawing.
SBC: ACETAMINOPHEN TOXICITY DIAGNOSTICS, LLC Topic: 300James, Laura P Project Summary/Abstract The original plan for development of AcetaSTAT was to use banked samples of serum collected from acetaminophen overdose patients to verify the effectiveness of the assay prior to verification and validation efforts. However, during the development of the work it has become apparent that banked samples cannot be used due to their instability and repeated expo ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Commercialization Readiness for Bone Filler Scaffold Device to Aid in Dental Applications and Reconstruction
SBC: NuShores Biosciences LLC Topic: NIDCRProject Summary Current bone grafting techniques for functional rehabilitation with dental implants have limitations – high-cost, difficulties with fixation and stabilization, insufficient bone regeneration, high morbidity using autogenous block grafts and prolonged healing of up to 9 months. Existing synthetic bone fillers cannot match defect shape and volume, are weakly resorbed if at all, are ...
SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Promoting adult hippocampal neurogenesis in Alzheimer's Disease using an antibody-based therapy
SBC: BOLDEN THERAPEUTICS, INC. Topic: RPROJECT SUMMARY Alzheimer's disease (AD) is a looming public health crisis that threatens millions of patients' ability to experience healthy aging. In addition to the challenges that AD poses to patients, healthcare providers and caregivers, there is also tremendous economic burden associated with AD and related dementias – estimated to be well over $200B/year in the United States alone. Hundre ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Plans4Care: Personalized Dementia Care On-Demand
SBC: Plans4Care INC Topic: RPROJECT ABSTRACT Although rt11 million family/friends are caregivers to rt6 million people with Alzheimer's Disease (AD) and AD- Related Dementias (AD/ADRD), they do not typically receive personalized education, strategies and support to manage their own wellbeing and complex dementia-related symptoms. Lack of personalized care contributes to $321 billion annually in AD/ADRD care costs. In respons ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health